EULAR REPURPOSING RHEUMATOLOGY DRUGS FOR COVID-19 12.02.2021 Kilchberg, EULAR has released new points to consider on the use of immunomodulatory drugs in Switzerland the fight against severe COVID-19 — COVID-19 is the disease caused by infection with the SARS-CoV-2 virus. [...] A EULAR taskforce was set up to develop a set of new points to consider to give guidance and advice on the best way to use these medicines to treat COVID-19. [...] Separate recommendations are available for the management of people with RMDs in the context of the pandemic. [...] EULAR aims to reduce the burden of RMDs on individuals and society and to improve the treatment, prevention and rehabilitation of RMDs. [...] It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with EULAR Page 2 of 2 PRESS RELEASE RMDs by the EU institutions through advocacy action.
Authors
- Pages
- 2
- Published in
- Switzerland
